Outcomes of 3-year follow up with induction vs first line chemotherapy in oral cancer patients: An observational hospital-based study

Pranab Kumar Sahoo; Anup Kumar Bhowmick; Sinjini Sarkar; Sutapa Mahata; Ranita Pal; Tanuma Mistry; Sushmita Ghosh; Trisha Choudhury; R Suresh Kumar; Syamsundar Mondal; Sriparna Datta; Partha Nath; Kalyan Kusum Mukherjee; Vilas D Nasare

doi:10.4103/jcrt.jcrt_2179_22

Outcomes of 3-year follow up with induction vs first line chemotherapy in oral cancer patients: An observational hospital-based study

J Cancer Res Ther. 2024 Jan 22. doi: 10.4103/jcrt.jcrt_2179_22. Online ahead of print.

Authors

Affiliations

¹ Department of Pathology and Cancer Screening, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
² Department of Pharmaceutical and Fine Chemical Technology, University of Calcutta, Kolkata, West Bengal, India.
³ Department of ENT Oncology, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
⁴ Department of Molecular Genetics, National Institute of Cancer Prevention, Noida, Uttar Pradesh, India.
⁵ Department of Epidemiology and Biostatistics, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
⁶ Department of Medical Oncology, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.

PMID: 38261440
DOI: 10.4103/jcrt.jcrt_2179_22

Abstract

Objective: Our study aims to analyse and compare the efficacy, adverse effect profile and survival among the Paclitaxel/Cisplatin/5-Flurouracil (TPF) induction chemotherapy and Paclitaxel/carboplatin (PC) first line or cisplatin chemotherapy in a high-volume tertiary care cancer centre.

Materials and methods: 215 patients with oral cavity cancer were recruited in this study. Patients with stages I-IIc underwent surgical resection or radiation therapy 66-74 GY/fraction. Patients of Stages III-IV were administered with either induction chemotherapy TPF or PC or cisplatin regimen. Treatment responses were assessed by CT and MRI. Response rates, survival and adverse effects data were tabulated and analysed.

Results: The mean age was 49.2 ± 11.68 years. Symptoms were ulceration (33.5%), growth (20.5%), pain (13%), ulcer-proliferative growth (8.4%) and swelling (13, 6%). The tumour site was found at the base of the tongue, C01 (42.2%) followed by C06 (35.8%), C08 (6.5%), C07 (5.2%) and C05 (4.6%). There were no significant differences (P > 0.05) in efficacy and survival outcomes between the different groups of treatment. Median survival was achieved within 36 months. The major side effect observed were anaemia (15.81%), diarrhoea (36.2%), dyspepsia (28.8%), fever (33.95%), mucositis (28.85%), myalgia (33.95%) and nausea (7.9%). Survival among the responder categories (CR, PR and NR) was significantly different as per Log-rank analysis (P = 0.015).

Conclusions: TPF induction therapy and PC first line chemotherapy showed similar efficacy, safety profile and survival whereas cisplatin shows poor efficacy and safety and survival in Indian oral cancer patients.